サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1436223

デュシェンヌ型筋ジストロフィーの世界市場レポート 2024年

Duchenne Muscular Dystrophy Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
デュシェンヌ型筋ジストロフィーの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

デュシェンヌ型筋ジストロフィーの市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には8.2%の年間複合成長率（CAGR）で16億1,000万米ドルに成長すると予想されています。予測期間中に予想される成長は、遺伝子治療の出現、精密医療アプローチ、治療へのアクセスの拡大、長期追跡研究、規制の進歩によるものと考えられます。予測期間の主要動向には、デジタルヘルス技術の統合、治療法、遺伝子治療、遺伝子医薬品の技術進歩、希少疾病用医薬品や精密医療アプローチに対する規制上の支援が含まれます。

デュシェンヌ型筋ジストロフィー市場の成長は、慢性疾患の有病率の増加によって促進されると予想されます。慢性疾患とは、症状が少なくとも1年間続く健康状態です。 デュシェンヌ型筋ジストロフィーは、この遺伝性疾患を持つ個人の特定の治療ニーズに対処するため、慢性疾患の蔓延に役割を果たしており、慢性疾患の影響を管理し、潜在的に軽減する上での個別化医療のより広範な重要性を強調しています。たとえば、生物医学と健康関連調査を専門とする米国政府機関である国立衛生研究所（NIH）は、2023年 1月の時点で、米国の労働年齢人口における慢性疾患の有病率が大幅に増加すると予測しています。この推定では、少なくとも1つの慢性疾患を有する50歳以上の成人が2020年から2035年までに99.5%増加することが示されています。さらに、多発性疾患の有病率は2020年から2050年にかけて110.5%急増すると予想されており、人々が直面する健康課題の増大を浮き彫りにしています。したがって、慢性疾患の有病率の増加は、デュシェンヌ型筋ジストロフィー市場の成長の重要な推進力です。

デュシェンヌ型筋ジストロフィー市場の成長は、個別化医療に対する需要の高まりによって促進されると予想されます。個別化医療には、遺伝子構造やライフスタイルなどの個人の固有の特性に合わせて医療を調整することが含まれ、より効果的かつ正確な医療結果につながります。 デュシェンヌ型筋ジストロフィー（DMD）の文脈では、個別化医療の適用には、個々の要因に基づいて治療をカスタマイズし、治療効果を高め、患者の転帰を改善することが伴います。たとえば、2023年12月の時点で、個別化医療の概念、サービス、製品の使用を促進する米国に本拠を置く非営利団体である個別化医療連合（PMC）の報告書によると、新たに承認されたNew Molecularの35％が個別化医療であることが明らかになりました。 これらは、2015年以降、承認された新治療薬の4分の1以上を一貫して占めています。過去6年間、個別化医療は常に新薬承認の3分の1以上を占めてきました。したがって、個別化医療に対する需要の高まりは、デュシェンヌ型筋ジストロフィー市場の成長の重要な推進力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界のデュシェンヌ型筋ジストロフィー市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界のデュシェンヌ型筋ジストロフィーの市場規模実績と成長、2018～2023年
  • 世界のデュシェンヌ型筋ジストロフィー市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界のデュシェンヌ型筋ジストロフィー市場、治療法別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 突然変異抑制
  • エクソンスキッピングアプローチ
  • 世界のデュシェンヌ型筋ジストロフィー市場、治療クラス別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 分子ベースの治療法
  • ステロイド治療法
  • 世界のデュシェンヌ型筋ジストロフィー市場、投与経路別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 経口
  • 非経口
  • その他
  • 世界のデュシェンヌ型筋ジストロフィー市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • 世界のデュシェンヌ型筋ジストロフィー市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 病院
  • 在宅医療
  • 専門クリニック
  • その他

第7章 地域と国の分析

  • 世界のデュシェンヌ型筋ジストロフィー市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
  • 世界のデュシェンヌ型筋ジストロフィー市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • デュシェンヌ型筋ジストロフィー市場の競合情勢
  • デュシェンヌ型筋ジストロフィー市場の企業プロファイル
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Eli Lilly and Company
    • Daiichi Sankyo Company Limited
    • PerkinElmer Inc.

第31章 その他の大手と革新的な企業

  • BioMarin Pharmaceutical Inc.
  • Nippon Shinyaku Co. Ltd.
  • Sarepta Therapeutics Inc.
  • PTC Therapeutics Inc.
  • Acceleron Pharma Inc.
  • FibroGen Inc.
  • Asklepios BioPharmaceutical Inc.
  • Catabasis Pharmaceuticals Inc.
  • Wave Life Sciences Ltd.
  • Bristol Myers Squibb Company
  • BridgeBio Pharma Inc.
  • CureVac NV
  • Rocket Pharmaceuticals Inc.
  • Italfarmaco SpA
  • Solid Biosciences Inc

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

目次
Product Code: r15549

Duchenne muscular dystrophy is a genetic condition causing progressive muscle loss, impacting skeletal, cardiac, and lung muscles. It results from a mutation in the gene responsible for dystrophin production, a crucial protein for healthy muscle function.

Duchenne Muscular Dystrophy therapies involve mutation suppression and the exon skipping approach. Exon skipping, a prevalent form of alternative splicing, removes introns and intervals on a pre-mRNA molecule, typically functioning as exons of a gene, when forming the final mRNA. Therapeutic classes include molecular-based therapies and steroid therapy, administered through oral, parenteral, and other routes. These therapies are distributed via hospital pharmacies, online pharmacies, and retail pharmacies, serving end-users such as hospitals, homecare, specialty clinics, and others.

The duchenne muscular dystrophy market research report is one of a series of new reports from The Business Research Company that provides Duchenne muscular dystrophy optical components market statistics, including Duchenne muscular dystrophy optical components industry global market size, regional shares, competitors with a Duchenne muscular dystrophy optical components market share, detailed Duchenne muscular dystrophy optical components market segments, market trends, and opportunities, and any further data you may need to thrive in the Duchenne muscular dystrophy optical components industry. This Duchenne muscular dystrophy optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The duchenne muscular dystrophy market size has grown strongly in recent years. It will grow from $1.07 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth observed in the historical period can be attributed to advancements in genetic understanding and diagnostics, progress in clinical trials, increased patient advocacy and awareness, orphan drug designation and incentives, and collaborative research initiatives.

The duchenne muscular dystrophy market size is expected to see strong growth in the next few years. It will grow to $1.61 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The anticipated growth in the forecast period can be attributed to the emergence of gene therapies, precision medicine approaches, expanded access to therapies, long-term follow-up studies, and regulatory advancements. Major trends in the forecast period include the integration of digital health technologies, technological advancements in therapeutics, gene therapies, and genetic medicines, as well as regulatory support for orphan drugs and precision medicine approaches.

The growth of the Duchenne muscular dystrophy market is anticipated to be propelled by the increasing prevalence of chronic diseases. Chronic diseases are health conditions with enduring symptoms lasting for at least a year. Duchenne muscular dystrophy plays a role in the prevalence of chronic diseases as it addresses the specific therapeutic needs of individuals with this genetic disorder, underscoring the broader importance of personalized medicine in managing and potentially mitigating the impact of chronic conditions. For instance, as of January 2023, the National Institutes of Health (NIH), a U.S. government agency specializing in biomedical and health-related research, projects a significant increase in the prevalence of chronic diseases among the working-age population in the United States. The estimate indicates a 99.5% rise in adults aged 50 years and older with at least one chronic disease from 2020 to 2035. Moreover, the prevalence of multimorbidity is expected to surge by 110.5% from 2020 to 2050, highlighting the growing health challenges faced by the working population. Therefore, the increasing prevalence of chronic diseases is a key driver for the growth of the Duchenne muscular dystrophy market.

The growth of the Duchenne muscular dystrophy market is anticipated to be propelled by the increasing demand for personalized medicine. Personalized medicine involves tailoring medical treatment to an individual's unique characteristics, such as genetic makeup or lifestyle, leading to more effective and precise healthcare outcomes. In the context of Duchenne muscular dystrophy (DMD), the application of personalized medicine entails customizing treatments based on individual factors, enhancing therapeutic efficacy, and improving patient outcomes. For instance, as of December 2023, a report by The Personalized Medicine Coalition (PMC), a US-based nonprofit organization promoting the use of personalized medicine concepts, services, and products, reveals that personalized medicines constituted 35% of newly approved New Molecular Entities (NMEs) in 2021. They have consistently represented over a quarter of new therapeutics approved since 2015. Over the last six years, personalized medicines have consistently comprised more than a third of new drug approvals. Therefore, the growing demand for personalized medicine is a key driver for the Duchenne muscular dystrophy market's growth.

Technological advancements are a prominent trend gaining traction in the Duchenne muscular dystrophy market. Key companies within this market are intensifying their focus on technological advancements and investing in research and development to fortify their positions. For example, in April 2021, the Hamon Center for Regenerative Science and Medicine at the University of Texas Southwestern, a US-based public academic health science center, introduced an innovative gene therapy approach for treating mice with Duchenne muscular dystrophy (DMD). This approach utilizes CRISPR-Cas9-based techniques to restore a significant portion of the dystrophin protein, which is often deficient in many DMD patients. The researchers developed highly effective CRISPR-Cas9 nucleotide gene editing techniques to override the erroneous stop signal, leading to the restoration of 97% of the protein. This breakthrough involved the exploration of nucleotide gene editing techniques using cardiomyocytes derived from induced pluripotent stem cells (iPS cells) of DMD patients, demonstrating the successful restoration of the dystrophin protein.

Major players in the Duchenne muscular dystrophy market are directing their efforts towards product innovations, notably the development of the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). This innovative therapy involves introducing functional copies of the dystrophin gene into affected individuals, aiming to correct the genetic mutation responsible for the progressive muscle degeneration associated with DMD. For instance, in June 2023, Sarepta Therapeutics, a US-based biopharmaceutical company specializing in RNA-based treatments for rare and infectious diseases, announced the FDA approval of ELEVIDYS, marking a significant milestone as the first gene therapy for Duchenne Muscular Dystrophy. This pioneering one-time treatment employs advanced gene therapy technology to target the root cause of the disease genetically. The approval of ELEVIDYS represents a paradigm shift in DMD treatment, moving beyond traditional supportive care approaches. It holds the potential to enhance patients' quality of life and life expectancy, showcasing the transformative impact of gene therapy on addressing rare diseases.

In December 2022, Solid Biosciences, a US-based life sciences company dedicated to advancing a portfolio of neuromuscular and cardiac programs, acquired AavantiBio for an undisclosed amount. This strategic acquisition positions the combined company to concentrate on the development of a diverse range of neuromuscular and cardiac programs, with a focus on advancing SGT-003, Solid's next-generation gene transfer candidate designed for the treatment of Duchenne muscular dystrophy. AavantiBio, Inc., a US-based biotechnology company, specializes in developing gene therapies aimed at transforming the lives of patients with rare genetic diseases.

Major companies operating in the duchenne muscular dystrophy market report are Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, PerkinElmer Inc., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Acceleron Pharma Inc., FibroGen Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., CureVac N.V., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., Nihon Pharmaceutical Co. Ltd., WAVE Life Sciences Ltd., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc.

North America was the largest region in the Duchenne muscular dystrophy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the duchenne muscular dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The duchenne muscular dystrophy market includes revenues earned by entities by providing respiratory therapy, physical therapy and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Duchenne Muscular Dystrophy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on duchenne muscular dystrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for duchenne muscular dystrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The duchenne muscular dystrophy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Therapy: Mutation Suppression; Exon Skipping Approach
  • 2) By Therapeutic Class: Molecular Based Therapies; Steroid Therapy
  • 3) By Route of Administration: Oral; Parenteral; Other Routes Of Administration
  • 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users
  • Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; Eli Lilly and Company; Daiichi Sankyo Company Limited; PerkinElmer Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Duchenne Muscular Dystrophy Market Characteristics

3. Duchenne Muscular Dystrophy Market Trends And Strategies

4. Duchenne Muscular Dystrophy Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Duchenne Muscular Dystrophy Market Size and Growth

  • 5.1. Global Duchenne Muscular Dystrophy Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Duchenne Muscular Dystrophy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Duchenne Muscular Dystrophy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Duchenne Muscular Dystrophy Market Segmentation

  • 6.1. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Mutation Suppression
  • Exon Skipping Approach
  • 6.2. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Molecular Based Therapies
  • Steroid Therapy
  • 6.3. Global Duchenne Muscular Dystrophy Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • Other Routes Of Administration
  • 6.4. Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • 6.5. Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End-Users

7. Duchenne Muscular Dystrophy Market Regional And Country Analysis

  • 7.1. Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Duchenne Muscular Dystrophy Market

  • 8.1. Asia-Pacific Duchenne Muscular Dystrophy Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Duchenne Muscular Dystrophy Market

  • 9.1. China Duchenne Muscular Dystrophy Market Overview
  • 9.2. China Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Duchenne Muscular Dystrophy Market

  • 10.1. India Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Duchenne Muscular Dystrophy Market

  • 11.1. Japan Duchenne Muscular Dystrophy Market Overview
  • 11.2. Japan Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Duchenne Muscular Dystrophy Market

  • 12.1. Australia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Duchenne Muscular Dystrophy Market

  • 13.1. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Duchenne Muscular Dystrophy Market

  • 14.1. South Korea Duchenne Muscular Dystrophy Market Overview
  • 14.2. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Duchenne Muscular Dystrophy Market

  • 15.1. Western Europe Duchenne Muscular Dystrophy Market Overview
  • 15.2. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Duchenne Muscular Dystrophy Market

  • 16.1. UK Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Duchenne Muscular Dystrophy Market

  • 17.1. Germany Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Duchenne Muscular Dystrophy Market

  • 18.1. France Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Duchenne Muscular Dystrophy Market

  • 19.1. Italy Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Duchenne Muscular Dystrophy Market

  • 20.1. Spain Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Duchenne Muscular Dystrophy Market

  • 21.1. Eastern Europe Duchenne Muscular Dystrophy Market Overview
  • 21.2. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Duchenne Muscular Dystrophy Market

  • 22.1. Russia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Duchenne Muscular Dystrophy Market

  • 23.1. North America Duchenne Muscular Dystrophy Market Overview
  • 23.2. North America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Duchenne Muscular Dystrophy Market

  • 24.1. USA Duchenne Muscular Dystrophy Market Overview
  • 24.2. USA Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Duchenne Muscular Dystrophy Market

  • 25.1. Canada Duchenne Muscular Dystrophy Market Overview
  • 25.2. Canada Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Duchenne Muscular Dystrophy Market

  • 26.1. South America Duchenne Muscular Dystrophy Market Overview
  • 26.2. South America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Duchenne Muscular Dystrophy Market

  • 27.1. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Duchenne Muscular Dystrophy Market

  • 28.1. Middle East Duchenne Muscular Dystrophy Market Overview
  • 28.2. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Duchenne Muscular Dystrophy Market

  • 29.1. Africa Duchenne Muscular Dystrophy Market Overview
  • 29.2. Africa Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Duchenne Muscular Dystrophy Market Competitive Landscape And Company Profiles

  • 30.1. Duchenne Muscular Dystrophy Market Competitive Landscape
  • 30.2. Duchenne Muscular Dystrophy Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. GlaxoSmithKline plc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Eli Lilly and Company
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Daiichi Sankyo Company Limited
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. PerkinElmer Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Duchenne Muscular Dystrophy Market Other Major And Innovative Companies

  • 31.1. BioMarin Pharmaceutical Inc.
  • 31.2. Nippon Shinyaku Co. Ltd.
  • 31.3. Sarepta Therapeutics Inc.
  • 31.4. PTC Therapeutics Inc.
  • 31.5. Acceleron Pharma Inc.
  • 31.6. FibroGen Inc.
  • 31.7. Asklepios BioPharmaceutical Inc.
  • 31.8. Catabasis Pharmaceuticals Inc.
  • 31.9. Wave Life Sciences Ltd.
  • 31.10. Bristol Myers Squibb Company
  • 31.11. BridgeBio Pharma Inc.
  • 31.12. CureVac N.V.
  • 31.13. Rocket Pharmaceuticals Inc.
  • 31.14. Italfarmaco SpA
  • 31.15. Solid Biosciences Inc

32. Global Duchenne Muscular Dystrophy Market Competitive Benchmarking

33. Global Duchenne Muscular Dystrophy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Market

35. Duchenne Muscular Dystrophy Market Future Outlook and Potential Analysis

  • 35.1 Duchenne Muscular Dystrophy Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Duchenne Muscular Dystrophy Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Duchenne Muscular Dystrophy Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer